Tripos Names New VP of Business Development and Strategic Alliances, Discovery Research
News Dec 16, 2005
Tripos, Inc. has announced that it has appointed Dr. Tom Mander as vice president of business development and strategic alliances, Discovery Research.
In his new role, Mander will be responsible for identifying new business development opportunities, establishing strategic alliances, developing intellectual property, and driving marketing initiatives for Tripos Discovery Research, Ltd. (TDR), which is located in Bude, England.
"Tom possesses an ideal blend of scientific expertise, leadership skills and international business development experience that will contribute to TDR’s continued evolution," said Dr. Mark Allen, senior vice president and managing director of TDR.
Mander brings 13 years of experience in small molecule drug discovery to Tripos. For the past six and a half years, Mander has held a variety of operational and commercial roles at Evotec, including department manager, product manager and vice president of business development.
He is credited with pioneering Evotec’s biological service offerings, launching several new products lines including Compound Management, establishing new strategic partnerships, and creating new business models.
Before joining Evotec, Mander was a group leader at Glaxo Wellcome, and held senior scientific roles at Xenova Ltd., the Centre for Natural Product Research (now MerLion) and Amersham International (now GE Healthcare).
"I am delighted to have joined Tripos Discovery Research," Mander said.
"It has established an unsurpassed level of expertise in high throughput parallel and analytical chemistry in a truly unique location conducive to innovation and creativity on behalf of its partners."
"I am looking forward to utilizing my experience to drive the company forward as we begin a new era at Tripos."
Mander holds a Doctor of Philosophy degree in a study of the physiological roles of microglia (brain macrophages) from the University of Oxford, a master of business administration degree from the Open University, and a bachelor’s degree in medical biochemistry from the School of Biological Sciences at the University of Surrey.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018